Here are your MiTeGen Hottest Tweets in SBDD with DARPin scaffolds stealing the show cracking tough...
MiTeGen Hottest Tweets in SBDD (10/23)
This month, your MiTeGen Hottest Tweets in SBDD tweets come in the wake of the Ozempic frenzy. The increasing popularity of GLP-1 class weight-loss drugs, which reduce appetite and improve obesity-related disorders, has led experts to predict that over the next decade, people could lose a staggering number of pounds, which in turn, will massively shift the economic landscape. And of course, there were many other exciting developments, which you can find below:
Tough drug targets
Activation of human STING by a molecular glue-like compound | Nat Chem Biolhttps://t.co/vEBiHPBKhh#CryoEM #MembraneProteins pic.twitter.com/EZUjGmdUrC
— Membrane Protein PDB (@MemProtPDB) October 12, 2023
#ER_literature The cryo-EM structure of the human ERAD retrotranslocation complex | Science Advances https://t.co/HTz2B3Q9JG
— Eric Chevet (@Eric_Chevet) October 14, 2023
Happy to publish our work on the allosteric inhibition mechanism of P2X4 receptors by a combination of cryo-EM, MD simulations, and electrophysiology @NatureComms.
— Motoyuki Hattori (服部素之) (@HattoriLab) October 14, 2023
Great collaboration with Dr. Wang at CPU. Congrats to Cheng Shen and all others involved!https://t.co/loCN0zLPq9
Check out this thread on our story on activation of PRC2 through automethylation and dimerization! Awesome team effort from @paulvictorsauer, Egor Pavlenko, @poepsel_lab, @trincookis @KarissaScience and the rest of our twitterless collaborators! https://t.co/sfNCn9c62S
— The Nogales Lab (@NogalesLab) October 14, 2023
Structural basis of promiscuous substrate transport by Organic Cation Transporter 1
— TKato (@oxkawaka) October 12, 2023
ついに最後のOCTチームが構造出してきたなhttps://t.co/3hfS43qmMk
CryoEM structure of a therapeutic antibody (favezelimab) bound to human LAG3 determined using a bivalent Fab as fiducial marker https://t.co/Xv78k70wV4
— Structure (@Structure_CP) October 6, 2023
The fantastic @yyang_cella extracted #Abeta40 filaments from the meninges of 3 cases of AD & CAA. Her (up to 2.4A resolution) structures redefine the #Abeta40 fold as reported by Kollmer et al in 2019.
— Sjors Scheres (@SjorsScheres) October 8, 2023
As always with @MichelGoed https://t.co/cUmaejS8lH
Paper week continues - now with @thgeweri and her work on Pgp's transport mechanism https://t.co/mezG2qwbSJ Great collaboration with Ina Urbatsch and Qinghai Zhang. @MPIbp @UniOsnabrueck #CellNanOs #cryoEM pic.twitter.com/c7XhC5XywY
— Arne Moeller (@MoellerGroup) October 6, 2023
Will tuning down constitutive activity of GPR61 with inverse agonism be therapeutically useful in some to promote hyperphagia? @pfizer @NatureComms https://t.co/u1iVO50iP4 pic.twitter.com/BRf6yCb86G
— Daniel J Drucker (@DanielJDrucker) September 24, 2023
The weird and wonderful
Thrilled to announce our latest preprint revealing the structure of endosomal tether CORVET! Incredible teamwork with Caro König and Nicole Susan. Check it out! @MoellerGroup @UngermannLab @UniOsnabrueck #sfb1557 #cryoEM pic.twitter.com/4l0i1O7ZSc
— Dmitry Shvarev (@DmitryShvarev) October 14, 2023
How beautiful is this 😍 https://t.co/xQBAtGpkeE pic.twitter.com/YxjwrGuhCv
— Marta Siborova (@HangryHobbit) September 18, 2023
Remember your high school biology textbook saying bacteria don't have histones? Turns out, researchers have proven otherwise! Check out LMS researchers' study to learn more!@tobias_warnecke @antoine_hocher @NatureMicrobiol #HistonesInBacteria #Microbiology https://t.co/ARBuCqUPbE pic.twitter.com/0C0IHRlXYI
— MRC Laboratory of Medical Sciences (MRC LMS) (@MRC_LMS) October 9, 2023
Want to know what happens when mitochondria get stressed? Check our latest pre-print with @SimoneMattei19 lab on how mitochondria tether hibernating ribosomes as an adaptive response to glucose depletion in yeast!https://t.co/G7Ku5KKIsX#teamtomo #cryoEM #ribosomes #mitochondria pic.twitter.com/BjPkDK4vNq
— Ahmad Jomaa (@jomaa_lab) October 9, 2023
Our #CryoEM study on the uroplakin complex in porcine urothelium is now officially published! Appreciate the beautiful crystalline lipids! https://t.co/oK6im3w7Ke pic.twitter.com/rWrIicDWUi
— tshykd (@tshykd) October 7, 2023
Sample preparation
Finally could share my work in the last two years. We were able to obtain 10 high resolution structures from supermarket spinach leaves. With that I am looking for jobs that could support me further persuing this direction. https://t.co/MQGEXl3O3A
— kaituo wang (@kaituowang) October 15, 2023
We tried to measure #CryoEM ice thickness via @CryoSolWorld VitroJet. Excited about your feedback on https://t.co/KJZNPJn9OV
— Daniel Mann (@proteincommandr) October 10, 2023
The Marta Carroni way of fast microscope loading! pic.twitter.com/q3BnPwwqRL
— Israel Fernandez (@IsraelF96135088) October 7, 2023
When 1980s myths saying you need to cleave tags to get structures meets reality https://t.co/8fGL7nbTy1
— Kelvin Lau always @klausenhauser on ☁️ 🪡 🐘 (@klausenhauser) September 25, 2023
#cryoem pic.twitter.com/QlXaLhzsJD
— Shane Gonen (@GonenShane) September 24, 2023
Better imaging
Hey #cryoEM ! What total electron exposure do we like for small protein (less than 100 kDa) single particle these days? Is 50 enough? Is it worth going out to 75 or 100 electrons per angstrom^2?
— Sara J. Weaver, Ph.D. (@sarajweaver) October 11, 2023
Jason de la Cruz and I reviewed how growth in #cryoEM technology across the three main TEM modalities is helping cryoEM mature as a tool & enabling new research paths.
— Edward Eng (@edward_eng) October 10, 2023
Our open access article - Scaling up cryoEM for biology and chemistry… is now online:https://t.co/Qr3QcHDWGj
1.46 Å performance at JEOL demo lab!
— Direct Electron (@DirectElectron) October 3, 2023
Researchers at JEOL in Japan installed Apollo on their microscope and generated the highest resolution (1.46 Angstrom) CryoEM data they had ever achieved on their scope, which was previously equipped with a Gatan K3.https://t.co/FfX07BT2zu pic.twitter.com/WdELKKnbv0
95% of Krios data ends up in papers. This is how you do it. 👍 https://t.co/79mhaZXvq4
— Basil Greber (@BJ_Greber) September 30, 2023
Processing and IT
What our learners say - "This is exactly how it should be taught. I love you guys so much!" And we love that our approach helps you understand and enjoy learning biology. Thank you! Sign up today to feel the love at https://t.co/15OEgSiMMK #love #learning #biology pic.twitter.com/LIqCqzBLrU
— Smart Biology (@SmartBiology3D) October 14, 2023
New Title Alert: CryoREAD is a computational tool using deep learning to automatically build full DNA/RNA atomic structure from cryo-EM map.
— SBGrid: Structural Biology Software (@SBGrid) October 11, 2023
Read more here: https://t.co/RPknKOVjX4#atomicstructure #cryo-EM #science pic.twitter.com/eTudqkYIfB
New paper from my group out in https://t.co/exum8zdZ0f. Outstanding work by Ben Porebski and great collaboration with https://t.co/xTxToaSswv. We describe a new high-throughput strategy for biomolecular discovery, which we call deep screening. pic.twitter.com/gVHdOm2HBV
— Phil Holliger (@PhilHolliger) October 10, 2023
We will also again have an engaging panel discussion on emerging technologies and data management. Check out the packed agenda here: https://t.co/28bOh4FmQq pic.twitter.com/aJVVaZRKHM
— Christopher Arthur (@cparthurphd) October 2, 2023
Forget about the contrast transfer function... this is mostly #cryoem pic.twitter.com/lhS4CE3Jea
— Matthew Belousoff (@bluesocks81) October 2, 2023
How much data is really necessary for a high resolution structure by #cryoEM?
— Proteoma (@ProteomaCryoEM) September 22, 2023
The answer may be less than you think, depending on your target resolution and the data quality.
Below is a 2.8Å map of a GPCR generated from 150 movies. pic.twitter.com/xc1zYg7436
Thoughts and opinions
the problem with working in industry is there are no professors trying to ruin my life https://t.co/L20kOoeDEM
— David Dranow 🇮🇱 (@GntlmnScientist) October 11, 2023
Asked Microsoft Copilot's preview to "Make a figure illustrating the cryo-electron tomography workflow". It is not there yet, but maybe getting close.🙂
— Rado Danev (@RadoDanev) October 10, 2023
On the other hand, it is very good at "mouse eating a cake".🍰🐭🙂👍 pic.twitter.com/bwpyFUG78n
Listed to Katalin Kariko and Carl June speak back to back. Neither had RO1 grants. People thought they were crazy. They were begging for money. The Peer Review system needs reform. More risk taking. Scientists should not have to do the work before they get a grant.
— Robert Nelsen (@rtnarch) October 5, 2023
The take home message is that even if the entire world tells you that you're working on something unimportant and you struggle to get funding or keep a job there's a one in a million chance you'll get a prize with which you could buy a two rooms apartment multiple decades later
— Oded Rechavi 🦉 (@OdedRechavi) October 3, 2023
I know Krios screening used to be frowned upon, but looking at our own results, I would say that Krios screening using short sessions is still faster than Glacios screening (for the same resolution) and could potentially be very effective if organised correctly.
— Basil Greber (@BJ_Greber) October 1, 2023
Is Target-Based Drug Discovery Efficient? https://t.co/rt8vzIMPdu
— Paras Sharma (@paras_biotech) September 24, 2023
Derek Lowe's take on it -https://t.co/U7eqv035gA
Biotech news and drug discovery technologies
"Novartis said that its top priority for CAR T therapies is now autoimmune diseases, even over cancer"
— Professor Oak (@Prof_Oak_) October 13, 2023
Nice comments from Richard Siegel, Head of Immunology at $NVS. Ongoing study of YTB323 will enroll older and sicker patients than Schett IST, with data "within a year" https://t.co/8j0IOSI80P
The VC financing remains active in biotech pic.twitter.com/99lQzVTcJ1
— Paras Sharma (@paras_biotech) October 8, 2023
With $XBI at 52 week lows
— Wilson Cheung (@Sanctuary_Bio) October 2, 2023
36.6% of biotechs trade under cash
Over half of biotechs (51%) under $300M mc (microcaps) trade under cash
Ozemphoria
We had a good run pic.twitter.com/5lxLVn7aeu
— Buyback Capital (@Larryjamieson_) October 13, 2023
Amazing that Ozempic is actually affecting @Walmart food sales!
— Elon Musk (@elonmusk) October 6, 2023
While no drug is without side effects, health problems associated with obesity almost certainly exceed the risks of GLP-1 agonists.
Weight loss drug Ozempic causing selloff in candy and beer stocks, per Bloomberg.
— Genevieve Roch-Decter, CFA (@GRDecter) October 6, 2023
Walmart said it's already seeing an impact on shopping demand from people taking Ozempic.
That sent shares of food and beverage companies sliding, some to multiyear lows.
Crazy. pic.twitter.com/2EGBMEFxXo
Another huge win for GLP-1, semaglutide and PPL with #T2D at risk of developing #kidney disease. FLOW stopped early for efficacy @novonordisk https://t.co/yiXZbCnrUC pic.twitter.com/ffu9QuTNad
— Daniel J Drucker (@DanielJDrucker) October 10, 2023
OK!
— Paras Sharma (@paras_biotech) October 14, 2023
Per Numerator data (conducted in 500 people), current Ozempic users are likely buying significantly less food and beverages, especially snacks and higher carb products pic.twitter.com/Is4VySPGDp
1/ Just caught up with a few investor friends in the consumer space last week about Ozempic and GLP1s
— Corry Wang (@corry_wang) October 11, 2023
As far as I can tell, everything basically hinges on: how much does it matter that every consumer product in the world depends on a tiny cohort of super consumers?
The rich get richer with $NVO stopping semaglutide CKD trial early for efficacy.
— Peter Suzman (@Biomaven) October 11, 2023
Weight loss, cardiac mortality improvement and now likely improved kidney function in diabetics.
This will surely be the world's biggest selling drug ever.
I guess we wont need any medical devices when everyone is skinny
— Dan Rosenblum (@sharkbiotech) October 11, 2023
or at least thats how the stocks are acting
Is there no such thing as good news? pic.twitter.com/Qp6BSbT2gp
— Morgan Housel (@morganhousel) October 11, 2023
Davita (dialysis provider) stock is ⬇️ in response to @novonordiskus stopping FLOW
— Beverly G. Tchang, MD (@BevTchangMD) October 11, 2023
What other end stage chronic disease markets will be affected?
Bloomberg is calling it the #OzempicEffect @business @markets https://t.co/Op9ynSGjpt#diabetes #obesity #endocrine #nephrology…
It's "Glip-1" and if you say otherwise, you're wrong.
— Adam Feuerstein (@adamfeuerstein) October 13, 2023
Also, a hot dog IS NOT a sandwich. https://t.co/0wHhu3ZhvC
Has anyone tried ozempic together with roids? seems like a powerful combo to take civilization to the next level.
— dalibali (@dalibali2) October 13, 2023
@tradedollarnut @mfwarder:
— Daniel Thomas (@MathmagicMan) October 12, 2023
The real question is, how will AMR recover from the GLP-1 (Ozempic) headwinds?
People lose weight -> they're more likely to go on dates -> fewer people live alone -> less housing demand -> industrial steel demand decreases -> met coal prices drop
Short sellers have increased their bets against restaurant stocks over concerns about higher interest rates and weight-loss drugs such as Ozempic, per Bloomberg.
— unusual_whales (@unusual_whales) October 10, 2023
Brand name idea: Stopgovy 🥳 https://t.co/2LMxGzsM1v
— Matt Warder (@mfwarder) October 12, 2023
As people lose weight thanks to Ozempic, they'll be more inclined to skip the elevator & take the stairs. Short $OTIS. 👍
— Marc Slans (@marc_slans) October 11, 2023
This Ozempic narrative is out of control.
— Charioteer Investing (@Chariot_Invest) October 13, 2023
That being said, the 2nd derivative play on this would be to go long airlines. Each pound of weight savings saves the airline hundreds of thousands of dollars in fuel costs over the airplanes operating life.
Joking, but not joking
Anti-obesity medications like Ozempic are becoming increasingly popular.
— The Kobeissi Letter (@KobeissiLetter) October 11, 2023
Bank of America expects 48 million US patients on anti-obesity medications by 2030.
Currently, there are just ~1 million patients using the medications in the US.
The movement into anti-obesity… pic.twitter.com/ULINLB60qA
What the Wegovy shortage looks like for doctors — and for patients https://t.co/dgIiKmDAsA
— Matthew Herper (@matthewherper) October 11, 2023
Key Patent Timelines for Weight Loss Drugs pic.twitter.com/iqIV050RPD
— Paras Sharma (@paras_biotech) October 14, 2023
Lots of interest in muscle loss, quality and strength after #weightloss with GLP-1-based therapies. Here Tirzepatide reduces the fat content of muscle, with modest changes in muscle volume #EASD2023 https://t.co/cRiO9CaxLc @EASDnews pic.twitter.com/FSP1BJXewL
— Daniel J Drucker (@DanielJDrucker) October 3, 2023
Alright…
— Citrini (@Citrini7) October 13, 2023
Here you go. I've removed the paywall on the article "Upgrading from Overweight: The Effect of GLP-1 Drugs on the Investment Landscape" published on July 11th, 2023.
Enjoy!https://t.co/HSl0bfEoQ4
There are some bargains in medtech now.
— Citrini (@Citrini7) October 14, 2023
I've pared back the short on the GLP-1 medtech names significantly, most of them are down 50-60%.
It's time to make a shopping list.
I'd say probably 6 out of every 10 names hit on this is from panic, and 4 will actually have issues.
GLP-1 mania is hilarious.
— McGriddle Connoisseur (@CloisterRes) October 11, 2023
Let's imagine GLP-1 reduces all CKD by 50%. (I would be shocked it's this high)
Now imagine as many patients are on GLP1s as statins (25%, also LMAO).
The reduction in total CKD is (drumroll.......)
12.5%.
At peak GLP1 market penetration.
HIDDEN FACTORS
— Brett Caughran (@FundamentEdge) October 11, 2023
On a day when NOVO's FLOW data (GLP-1) is rocking the med tech complex ($DVA -19%, $INSP -13%), I thought I'd comment on a concept that I've been thinking about a lot for the last 8 years - the concept of hidden factors and how thematic factors seem to be…
— 88888 (@88888sAccount) October 12, 2023
About MiTeGen
MiTeGen, founded in 2004 by Cornell University Professor Robert Thorne, is a leading provider of innovative technologies for cryo-EM, crystallography, and other techniques used for probing small molecule and biomolecular structure and function. Our mission is to support researchers in achieving the best possible results throughout the entire process, from sample preparation to data collection.
With a strong emphasis on collaboration, we actively work with academic, government, and industrial researchers in over 40 countries to develop and deliver new tools and methods. Our products have gained recognition and trust within the scientific community, as they have been cited in over 4,500 published research articles. By leveraging concepts and technologies from physics and related fields, we tackle practical challenges faced by our friends and collaborators in the life sciences and other disciplines.
Driven by a passion for cryo cooling, we would like to showcase three of our innovative cryo-EM solutions:
Manual Plunge Cooler and Precision Ethane Cryostat:
Our Manual Plunge Cooler and Precision Cryostat are specifically designed to streamline and optimize your cryo-EM sample vitrification workflow. These systems consist of three components that can be obtained individually or as a complete package, ensuring efficient and successful sample preparation.
Cryo-EM Starter Kits:
Our Cryo-EM starter kits are curated to equip your laboratory with all the necessary tools conveniently packaged together. These kits are ideal for labs aiming to perform basic grid and sample preparation for cryo-EM within their own facility, even on a reduced budget. The kit includes components essential for cryo-EM sample preparation, as well as sample storage and transport solutions.
Cryo-EM AutoGrid Cassette Puck:
Our latest addition, the Cryo-EM AutoGrid Cassette Storage and Shipping puck, builds upon the success of our 2nd generation Cryo-EM Puck. This innovative solution allows users to screen samples on a instrument and seamlessly ship the same AutoGrid cassette puck to a collection facility. It also serves as a convenient storage option for facilities, enabling them to store their cassettes in the puck canes designed to fit into cassette loading stations.
These cryo-EM solutions exemplify our dedication to enhancing cryo cooling capabilities and simplifying workflows in the field of cryo-EM. MiTeGen continues to push the boundaries of innovation, enabling researchers to advance their structural biology studies with greater ease and efficiency.
Contact us at MiTeGen today to arrange a no obligation consultation to learn how we can help you with your research.
